There is first-class research in Canada, and we've known that for a long time. I've worked in the biotech and pharmaceutical industry and been investing for many decades; I have invested in Canada.
I think the challenge in the AMR space specifically is that the market is broken, so investors are lacking. Trying to take innovation coming out of academia, advancing that, translating that into drugs and bringing those to patients is really the critical shortfall. Good ideas are just not financeable when investors won't invest, and that's the current state of affairs. That's why we need the pull incentives we've been talking about to make sure that there is a financial incentive in Canada and around the world to bring investors back into the field to ensure that innovation can advance and that we can have the new drugs that patients need desperately.